14,469 Shares in Moderna, Inc. $MRNA Purchased by Northwestern Mutual Wealth Management Co.

Northwestern Mutual Wealth Management Co. bought a new position in shares of Moderna, Inc. (NASDAQ:MRNA) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 14,469 shares of the company’s stock, valued at approximately $1,013,000.

Several other large investors have also recently bought and sold shares of MRNA. MUFG Securities EMEA plc acquired a new stake in Moderna during the second quarter worth approximately $28,000. Allied Private Wealth LLC bought a new stake in shares of Moderna during the second quarter worth approximately $30,000. Canton Hathaway LLC acquired a new position in shares of Moderna in the first quarter valued at approximately $31,000. EverSource Wealth Advisors LLC grew its position in shares of Moderna by 148.3% in the second quarter. EverSource Wealth Advisors LLC now owns 1,341 shares of the company’s stock valued at $37,000 after purchasing an additional 801 shares during the last quarter. Finally, Assetmark Inc. increased its stake in shares of Moderna by 35.1% during the first quarter. Assetmark Inc. now owns 801 shares of the company’s stock worth $41,000 after purchasing an additional 208 shares during the period. 75.33% of the stock is owned by institutional investors.

Moderna News Roundup

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Positive Phase 3 cancer-vaccine data remains the main catalyst. Moderna and Merck reported that intismeran, used with Keytruda, met key goals in the INTerpath-001 study of resected melanoma. The result is viewed as an important validation of Moderna’s mRNA technology because it reportedly showed benefit over Keytruda alone—the first positive late-stage readout for an mRNA-based cancer vaccine in this setting. Moderna’s personalized cancer vaccine shows promise
• Positive Sentiment: Analysts see a substantial opportunity. Wolfe Research estimates the melanoma and broader cancer-vaccine opportunity could reach approximately $9.2 billion, while other analysts have raised ratings and highlighted the long-term potential of intismeran. That has helped shift the investment narrative beyond Moderna’s declining COVID-19 business. MRNA Stock Jumps Past $150
• Positive Sentiment: Broader mRNA validation is supporting sentiment. The FDA’s approval of the first mRNA-based flu vaccine could improve perceptions of mRNA platforms and reinforce the value of related intellectual property, although the approval is not itself a direct Moderna product catalyst. FDA Approves First mRNA-Based Flu Vaccine
• Neutral Sentiment: Trading momentum is amplifying the move. A reported “Power Inflow” signal and unusually heavy volume indicate strong buying interest, but these technical indicators do not establish the vaccine’s long-term commercial value. Moderna Shares Rise After Trading Signal
• Negative Sentiment: Investors face significant execution and valuation risks. The cancer-vaccine evidence remains limited, and broader adoption could be constrained by manufacturing complexity, regulatory requirements, cost, competition and the need for additional data. Analysts also caution that Moderna’s pipeline and financial outlook remain challenging outside this program. Explainer on the Merck-Moderna Cancer Vaccine
• Negative Sentiment: Profit-taking and geopolitical concerns could increase volatility. Moderna previously fell as traders locked in gains after its extraordinary advance. CEO Stéphane Bancel also warned that China is investing heavily in biotechnology and mRNA, creating a potential long-term competitive threat. Moderna CEO Warns About China’s mRNA Investment

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on MRNA. William Blair raised Moderna from a “market perform” rating to an “outperform” rating in a report on Wednesday, August 19th. Morgan Stanley upped their price objective on Moderna from $39.00 to $89.00 and gave the company an “equal weight” rating in a report on Thursday, August 20th. Loop Capital set a $135.00 price objective on Moderna in a research report on Wednesday, August 19th. Barclays lifted their target price on Moderna from $48.00 to $125.00 and gave the stock an “equal weight” rating in a report on Monday. Finally, Citigroup boosted their target price on shares of Moderna from $41.00 to $60.00 and gave the company a “neutral” rating in a research report on Monday, August 3rd. Four investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, Moderna currently has an average rating of “Hold” and a consensus target price of $74.31.

Moderna Stock Up 14.4%

NASDAQ MRNA opened at $158.83 on Wednesday. The company has a current ratio of 2.29, a quick ratio of 2.18 and a debt-to-equity ratio of 0.09. The company has a market cap of $63.41 billion, a price-to-earnings ratio of -19.88 and a beta of 0.91. The company has a 50 day moving average of $72.29 and a 200-day moving average of $57.69. Moderna, Inc. has a 1-year low of $22.28 and a 1-year high of $176.66.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Friday, July 31st. The company reported ($1.97) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.03) by $0.06. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%.The business had revenue of $145.00 million for the quarter, compared to the consensus estimate of $102.93 million. During the same quarter in the prior year, the business posted ($2.13) earnings per share. The firm’s quarterly revenue was up 2.1% compared to the same quarter last year. On average, equities research analysts expect that Moderna, Inc. will post -6.18 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, President Stephen Hoge sold 53,336 shares of the firm’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $51.37, for a total value of $2,739,870.32. Following the transaction, the president owned 1,483,848 shares in the company, valued at approximately $76,225,271.76. This trade represents a 3.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Thyme Klinger sold 3,471 shares of the business’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $50.00, for a total value of $173,550.00. Following the completion of the transaction, the insider directly owned 67,468 shares of the company’s stock, valued at approximately $3,373,400. This trade represents a 4.89% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 10.80% of the company’s stock.

Moderna Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.